+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer

MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer

Cancer Cell International 16: 12

Prostate cancer (PCa) remains to be a diagnostic challenge due to its variable presentation and the lack of reliable diagnosis tool. MicroRNAs (miRNAs) regulate gene in extensive range of pathophysiologic processes. Plasma miRNAs are ideal biomarkers in heart failure, diabetes and other disease. However, using circulating miRNAs as biomarkers for the diagnosis of PCa is still unknown. 149 PCa patients, 57 healthy controls, and 121 non-cancer patients (benign prostatic hyperplasia and other urinary diseases) were enrolled in this study. The reverse transcription of miRNA and SYBR-Green-based double standards curve miRNA quantitative polymerase chain reactions (qPCR) were used to evaluate the dysregulated miR-410-5p. Receiver operator characteristic (ROC) curve analysis was used to evaluate the diagnostic accuracy of miR-410-5p identified as the alternative biomarker. Circulating miRNA-410-5p (miR-410-5p) level was significantly higher in the PCa patients than in healthy controls or non-cancer patients. ROC curve analysis showed that plasma miR-410-5p was a specific diagnostic biomarker of PCa with an area under curve(AUC) of 0.8097 (95 % confidence interval, 0.7371-0.8823; P < 0.001). The serum miR-410-5p level is a potential biomarker for the diagnosis of PCa.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058309732

Download citation: RISBibTeXText

PMID: 26900347

DOI: 10.1186/s12935-016-0285-6

Related references

Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer. Iranian Biomedical Journal 21(2): 106-113, 2018

Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. Molecular Neurobiology 53(1): 163-170, 2016

Serum microRNA-218 is a potential biomarker for esophageal cancer. Cancer Biomarkers 15(4): 381-389, 2016

MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. Journal of International Medical Research 46(3): 975-983, 2017

Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma. Cancer Biomarkers 15(5): 543-550, 2016

MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer. Cancer Biomarkers 17(2): 223-230, 2017

MicroRNA-150 as a Potential Biomarker in Diagnosis of Cancer: a Meta-Analysis. Clinical Laboratory 63(7): 1187-1197, 2018

Serum microRNA-155 as a potential biomarker to track disease in breast cancer. Plos One 7(10): E47003, 2013

The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer. Oncotarget 8(19): 31215-31226, 2017

Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker. Oncology Letters 11(2): 1201-1206, 2016

MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biology and Medicine 12(4): 328-341, 2016

A meta-analysis of microRNA-17 as a potential biomarker in diagnosis of colorectal cancer. Cellular and Molecular Biology 64(6): 86-93, 2018

A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochemical and Biophysical Research Communications 493(3): 1322-1328, 2017

Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical Chemistry 58(3): 610-618, 2012

Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Science 101(10): 2087-2092, 2010